Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213264906> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W3213264906 endingPage "1" @default.
- W3213264906 startingPage "1" @default.
- W3213264906 abstract "Cisplatin-based neoadjuvant chemotherapy (C-NAC) has been the standard of care in localized muscle-invasive bladder cancer (MIBC). However, the feasibility and benefit of C-NAC in elderly patients remain uncertain since this population has always been underrepresented in pivotal trials and is often barred from chemotherapy in routine practice because of their perceived frailty. Therefore, in order to evaluate the effectiveness of C-NAC in elderly patients with MIBS, we retrospectively reviewed the medical files of patients (cT2-4, N0-3, and M0) treated at our institution and aged 75 or older at the time of the first chemotherapy cycle. From May 2012 to March 2020, 51 patients aged 75 to 90 received C-NAC. Among them, 38 patients received methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) and 13 patients received gemcitabine and cisplatin (GC). In this study, the primary endpoint was the feasibility of C-NAC, evaluated as the percentage of patients who underwent at least four chemotherapy cycles. Overall feasibility of a complete four-cycle chemotherapy course was 75% (dose-dense MVAC [dd-MVAC]: 76%; GC: 69%). Incidence of grade 3-4 adverse events was 57%, mostly driven by hematological toxicity from dd-MVAC, and the incidence of febrile neutropenia was 6%. These results indicate the feasibility of C-NAC in elderly patients without any contraindication to cisplatin. A coordinated multidisciplinary approach, including a geriatric oncologist, may help to identify patients at increased risk for chemotherapy-induced toxicity, especially in patients aged 85 or older." @default.
- W3213264906 created "2021-11-22" @default.
- W3213264906 creator A5020529503 @default.
- W3213264906 creator A5023789638 @default.
- W3213264906 creator A5024088181 @default.
- W3213264906 creator A5027175466 @default.
- W3213264906 creator A5033220136 @default.
- W3213264906 creator A5048792367 @default.
- W3213264906 creator A5050237869 @default.
- W3213264906 creator A5052785498 @default.
- W3213264906 creator A5083299209 @default.
- W3213264906 creator A5084326149 @default.
- W3213264906 date "2021-07-23" @default.
- W3213264906 modified "2023-10-14" @default.
- W3213264906 title "Cisplatin-Based Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer: Is It Feasible?" @default.
- W3213264906 doi "https://doi.org/10.21926/obm.geriatr.2104183" @default.
- W3213264906 hasPublicationYear "2021" @default.
- W3213264906 type Work @default.
- W3213264906 sameAs 3213264906 @default.
- W3213264906 citedByCount "0" @default.
- W3213264906 crossrefType "journal-article" @default.
- W3213264906 hasAuthorship W3213264906A5020529503 @default.
- W3213264906 hasAuthorship W3213264906A5023789638 @default.
- W3213264906 hasAuthorship W3213264906A5024088181 @default.
- W3213264906 hasAuthorship W3213264906A5027175466 @default.
- W3213264906 hasAuthorship W3213264906A5033220136 @default.
- W3213264906 hasAuthorship W3213264906A5048792367 @default.
- W3213264906 hasAuthorship W3213264906A5050237869 @default.
- W3213264906 hasAuthorship W3213264906A5052785498 @default.
- W3213264906 hasAuthorship W3213264906A5083299209 @default.
- W3213264906 hasAuthorship W3213264906A5084326149 @default.
- W3213264906 hasBestOaLocation W32132649061 @default.
- W3213264906 hasConcept C121608353 @default.
- W3213264906 hasConcept C126322002 @default.
- W3213264906 hasConcept C143998085 @default.
- W3213264906 hasConcept C197934379 @default.
- W3213264906 hasConcept C2776694085 @default.
- W3213264906 hasConcept C2777132456 @default.
- W3213264906 hasConcept C2778239845 @default.
- W3213264906 hasConcept C2780258809 @default.
- W3213264906 hasConcept C2780352672 @default.
- W3213264906 hasConcept C2908647359 @default.
- W3213264906 hasConcept C71924100 @default.
- W3213264906 hasConcept C99454951 @default.
- W3213264906 hasConceptScore W3213264906C121608353 @default.
- W3213264906 hasConceptScore W3213264906C126322002 @default.
- W3213264906 hasConceptScore W3213264906C143998085 @default.
- W3213264906 hasConceptScore W3213264906C197934379 @default.
- W3213264906 hasConceptScore W3213264906C2776694085 @default.
- W3213264906 hasConceptScore W3213264906C2777132456 @default.
- W3213264906 hasConceptScore W3213264906C2778239845 @default.
- W3213264906 hasConceptScore W3213264906C2780258809 @default.
- W3213264906 hasConceptScore W3213264906C2780352672 @default.
- W3213264906 hasConceptScore W3213264906C2908647359 @default.
- W3213264906 hasConceptScore W3213264906C71924100 @default.
- W3213264906 hasConceptScore W3213264906C99454951 @default.
- W3213264906 hasIssue "4" @default.
- W3213264906 hasLocation W32132649061 @default.
- W3213264906 hasOpenAccess W3213264906 @default.
- W3213264906 hasPrimaryLocation W32132649061 @default.
- W3213264906 hasRelatedWork W2026791198 @default.
- W3213264906 hasRelatedWork W2085978374 @default.
- W3213264906 hasRelatedWork W2100029565 @default.
- W3213264906 hasRelatedWork W2379223378 @default.
- W3213264906 hasRelatedWork W2381460883 @default.
- W3213264906 hasRelatedWork W2467600633 @default.
- W3213264906 hasRelatedWork W2907995139 @default.
- W3213264906 hasRelatedWork W2987293068 @default.
- W3213264906 hasRelatedWork W3202515919 @default.
- W3213264906 hasRelatedWork W48576449 @default.
- W3213264906 hasVolume "5" @default.
- W3213264906 isParatext "false" @default.
- W3213264906 isRetracted "false" @default.
- W3213264906 magId "3213264906" @default.
- W3213264906 workType "article" @default.